BRPI0508219A - métodos e composições para a detecção de contaminantes microbianos em soluções de diálise peritoneal - Google Patents

métodos e composições para a detecção de contaminantes microbianos em soluções de diálise peritoneal

Info

Publication number
BRPI0508219A
BRPI0508219A BRPI0508219-6A BRPI0508219A BRPI0508219A BR PI0508219 A BRPI0508219 A BR PI0508219A BR PI0508219 A BRPI0508219 A BR PI0508219A BR PI0508219 A BRPI0508219 A BR PI0508219A
Authority
BR
Brazil
Prior art keywords
peritoneal dialysis
dialysis solutions
compositions
methods
gram
Prior art date
Application number
BRPI0508219-6A
Other languages
English (en)
Inventor
Leo Martis
Mehul Patel
Joseph A Giertych
James W Mongoven
Jacqueline A Kunzler
William F Owen Jr
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34887248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0508219(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of BRPI0508219A publication Critical patent/BRPI0508219A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • External Artificial Organs (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

MéTODOS E COMPOSIçõES PARA A DETECçãO DE CONTAMINANTES MICROBIANOS EM SOLUçõES DE DIáLISE PERITONEAL. A presente invenção refere-se a métodos e composições para a detecção de contaminantes microbianos em soluções de diálise peritoneal são fornecidos. Uma nova causa de peritonite asséptica foi descoberta: a peritonite asséptica associada com contaminação microbiana gram-positiva de uma solução de diálise. Peptidoglicano é um maior componente de uma parede celular bacteriana gram-positiva e desse modo pode servir como um marcador para bactérias gram-positivas. Neste contexto, teste para peptidoglicanos pode ser utilizado para efetivamente prevenir peritonite em pacientes que usam as soluções de diálise peritoneal, tais como soluções de diálise peritoneal que contêm um polímero de glicose incluindo uma icodextrina e similares.
BRPI0508219-6A 2004-02-27 2005-02-18 métodos e composições para a detecção de contaminantes microbianos em soluções de diálise peritoneal BRPI0508219A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/789,320 US7118857B2 (en) 2004-02-27 2004-02-27 Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions
PCT/US2005/005187 WO2005093087A1 (en) 2004-02-27 2005-02-18 Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions

Publications (1)

Publication Number Publication Date
BRPI0508219A true BRPI0508219A (pt) 2007-07-17

Family

ID=34887248

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508219-6A BRPI0508219A (pt) 2004-02-27 2005-02-18 métodos e composições para a detecção de contaminantes microbianos em soluções de diálise peritoneal

Country Status (17)

Country Link
US (4) US7118857B2 (pt)
EP (1) EP1720999B1 (pt)
JP (2) JP5334412B2 (pt)
KR (1) KR100940173B1 (pt)
CN (2) CN1918302A (pt)
AR (2) AR047900A1 (pt)
AT (1) ATE421997T1 (pt)
AU (1) AU2005226756B2 (pt)
BR (1) BRPI0508219A (pt)
CA (1) CA2555209A1 (pt)
DE (1) DE602005012574D1 (pt)
DK (1) DK1720999T3 (pt)
ES (1) ES2321631T3 (pt)
PL (1) PL1720999T3 (pt)
SG (2) SG158178A1 (pt)
TW (1) TWI344368B (pt)
WO (1) WO2005093087A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450079B2 (en) 2003-10-31 2013-05-28 Immunetics, Inc. Method for detecting bacteria
US7118857B2 (en) 2004-02-27 2006-10-10 Baxter International Inc. Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions
US8202248B2 (en) 2004-08-18 2012-06-19 Sequana Medical Ag Dialysis implant and methods of use
US20090239819A1 (en) * 2008-03-20 2009-09-24 Run Wang Peritoneal dialysis solution test method
US20090239238A1 (en) * 2008-03-20 2009-09-24 Baxter International Inc. Methods for measuring pro-inflammatory substance levels in dialysis solutions and dialysis components
MX2010010271A (es) 2008-03-20 2010-12-02 Baxter Int Destruccion de productos microbianos a traves de digestion enzimatica.
US20090269733A1 (en) * 2008-04-23 2009-10-29 Azko, Inc. Devices and Methods for the Rapid Analysis of Pathogens in Biological Fluids
US9348975B2 (en) 2008-05-02 2016-05-24 Baxter International Inc. Optimizing therapy outcomes for peritoneal dialysis
US8882700B2 (en) 2008-05-02 2014-11-11 Baxter International Inc. Smart patient transfer set for peritoneal dialysis
US8057679B2 (en) 2008-07-09 2011-11-15 Baxter International Inc. Dialysis system having trending and alert generation
EP2391404B1 (en) 2009-01-30 2013-01-16 Baxter International Inc. Transfer sets for therapy optimization
US8282829B2 (en) 2009-05-20 2012-10-09 Baxter International Inc. System and method for automated data collection of twenty-four hour ultrafiltration and other patient parameters using wired or wireless technology
US9020827B2 (en) * 2009-10-16 2015-04-28 Baxter International Inc. Peritoneal dialysis optimized using a patient hand-held scanning device
FR2955861B1 (fr) 2010-02-02 2013-03-22 Roquette Freres Polymeres solubles de glucose branches pour la dialyse peritoneale
US20140083869A1 (en) * 2011-02-09 2014-03-27 University Of Massachusetts Detection Of Endotoxins
US9861733B2 (en) 2012-03-23 2018-01-09 Nxstage Medical Inc. Peritoneal dialysis systems, devices, and methods
CA2830085A1 (en) 2011-03-23 2012-09-27 Nxstage Medical, Inc. Peritoneal dialysis systems, devices, and methods
EP2609918A1 (en) * 2011-12-27 2013-07-03 Zytoprotec GmbH Peritoneal dialysis fluid comprising a GSK-3 inhibitor
US8585635B2 (en) 2012-02-15 2013-11-19 Sequana Medical Ag Systems and methods for treating chronic liver failure based on peritoneal dialysis
TR201807961T4 (tr) * 2012-05-29 2018-06-21 Roquette Freres Glukoz polimerleri ve glukoz polimerlerinin hidrolizatlarının üretilmesine yönelik döngüleri dekontamine etme yöntemleri.
WO2014047770A1 (en) 2012-09-25 2014-04-03 General Electric Company Disposable container for bioburden sample collection and detection
US9227005B2 (en) * 2013-03-14 2016-01-05 Brian J LeBerthon Method and device for treating cancer
KR102318190B1 (ko) 2013-03-26 2021-10-28 로께뜨프레르 펩티도글리칸의 생물학적 분석법
US9382591B2 (en) * 2013-06-06 2016-07-05 Pall Corporation Compositions for detecting Alicyclobacillus microorganisms
CN103467608B (zh) * 2013-09-27 2015-08-26 华仁药业股份有限公司 艾考糊精及其制备方法
RU2641960C2 (ru) * 2013-12-16 2018-01-23 Дмитрий Анатольевич Складнев Способ обнаружения микробной и вирусной контаминации растворов и биологических жидкостей
JP6370390B2 (ja) * 2014-02-07 2018-08-08 ロケット フレールＲｏｑｕｅｔｔｅ Ｆｒｅｒｅｓ ペプチドグリカンの生物検定
US20170281845A1 (en) * 2016-04-04 2017-10-05 Medtronic, Inc. Peritoneal dialysate fluid generation system
US10769244B2 (en) 2016-08-26 2020-09-08 Sequana Medical Nv Systems and methods for managing and analyzing data generated by an implantable device
GB201616718D0 (en) * 2016-09-30 2016-11-16 Microbiosensor Limited Microbial sensing devices
US11559618B2 (en) 2017-05-24 2023-01-24 Sequana Medical Nv Formulations and methods for direct sodium removal in patients having severe renal dysfunction
WO2018237375A1 (en) 2017-06-24 2018-12-27 Nxstage Medical, Inc. METHODS AND SYSTEMS FOR PREPARING AND / OR PROCESSING PERITONEAL DIALYSIS FLUID
AU2018223035A1 (en) * 2017-10-03 2019-04-18 Medtronic, Inc. Peritoneal dialysate temperature regulation system
EP3758771A4 (en) 2018-02-28 2021-11-17 NxStage Medical Inc. LIQUID PREPARATION AND TREATMENT DEVICES, METHODS AND SYSTEMS
CN109264812A (zh) * 2018-11-13 2019-01-25 华仁药业股份有限公司 一种用于去除淀粉水解物中内毒素的方法
CN109400722A (zh) * 2018-11-13 2019-03-01 华仁药业股份有限公司 一种用于去除淀粉水解物中肽聚糖的方法
US11280788B2 (en) * 2019-01-31 2022-03-22 Fresenius Medical Care Holdings, Inc. Rapid diagnosis of peritonitis in peritoneal dialysis patients
AU2023232562A1 (en) 2022-03-08 2024-09-05 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761237A (en) 1981-07-10 1988-08-02 Baxter Travenol Laboratories, Inc. Peritoneal dialysis solution containing carbohydrate polymers
US4886789A (en) 1983-01-12 1989-12-12 M. L. Laboratories Plc Peritoneal dialysis and compositions for use therein
US6077836A (en) 1983-01-12 2000-06-20 Ml Laboratotries, Plc Peritoneal dialysis and compositions for use therein
US6248726B1 (en) 1985-06-22 2001-06-19 M L Laboratories Plc Method of peritoneal dialysis using glucose polymer solutions
ATE106410T1 (de) 1985-06-22 1994-06-15 Ml Lab Plc In kontinuierlicher peritonealdialyse verwendete polymere.
ATE119204T1 (de) 1986-12-03 1995-03-15 Wako Pure Chem Ind Ltd Reagenzien zur bestimmung von peptidoglykan und beta-1,3-glukan.
DE4242926C2 (de) 1992-12-18 1994-12-15 Fresenius Ag Dialyselösung für die Peritonealdialyse
AU667623B2 (en) 1993-01-19 1996-03-28 Baxter International Inc. Multiple chamber container
FR2716199B1 (fr) 1994-02-15 1996-04-26 Roquette Freres Procédé de fabrication d'un hydrolysat d'amidon à faible indice de polymolécularité, nouvel hydrolysat d'amidon ainsi obtenu et son utilisation en dialyse péritonéale.
DE19748290B8 (de) 1997-10-31 2009-09-03 Fresenius Medical Care Deutschland Gmbh Lösung für die Peritonealdialyse
US6770148B1 (en) 1998-12-04 2004-08-03 Baxter International Inc. Peritoneal dialysis solution containing modified icodextrins
JP2002037705A (ja) * 2000-07-26 2002-02-06 National Agricultural Research Organization 耐酸耐熱性細菌用抗菌剤
US20040121982A1 (en) 2002-12-20 2004-06-24 Leo Martis Biocompatible dialysis fluids containing icodextrins
US7118857B2 (en) 2004-02-27 2006-10-10 Baxter International Inc. Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions

Also Published As

Publication number Publication date
JP2011140519A (ja) 2011-07-21
US20100056990A1 (en) 2010-03-04
AU2005226756A1 (en) 2005-10-06
US8546097B2 (en) 2013-10-01
ATE421997T1 (de) 2009-02-15
EP1720999A1 (en) 2006-11-15
ES2321631T3 (es) 2009-06-09
JP5334412B2 (ja) 2013-11-06
US20130338102A1 (en) 2013-12-19
SG145769A1 (en) 2008-09-29
WO2005093087A1 (en) 2005-10-06
US7618392B2 (en) 2009-11-17
DE602005012574D1 (de) 2009-03-19
TWI344368B (en) 2011-07-01
DK1720999T3 (da) 2009-05-04
TW200538137A (en) 2005-12-01
AR047900A1 (es) 2006-03-01
CN1918302A (zh) 2007-02-21
KR100940173B1 (ko) 2010-02-03
US20050191717A1 (en) 2005-09-01
AU2005226756B2 (en) 2008-08-28
SG158178A1 (en) 2010-01-29
KR20060126571A (ko) 2006-12-07
PL1720999T3 (pl) 2009-07-31
US8859222B2 (en) 2014-10-14
US20060263842A1 (en) 2006-11-23
US7118857B2 (en) 2006-10-10
JP2007525506A (ja) 2007-09-06
AR098287A2 (es) 2016-05-26
EP1720999B1 (en) 2009-01-28
CA2555209A1 (en) 2005-10-06
CN101879181A (zh) 2010-11-10

Similar Documents

Publication Publication Date Title
BRPI0508219A (pt) métodos e composições para a detecção de contaminantes microbianos em soluções de diálise peritoneal
Meng et al. Characterization of Shiga toxin-producing Escherichia coli isolated from healthy pigs in China
Cody et al. A longitudinal 6-year study of the molecular epidemiology of clinical Campylobacter isolates in Oxfordshire, United Kingdom
Otsuka et al. Emergence of multidrug-resistant Corynebacterium striatum as a nosocomial pathogen in long-term hospitalized patients with underlying diseases
Aliakbarzade et al. Prevalence of aminoglycoside resistance genes in Acinetobacter baumannii isolates
Clark et al. Factors affecting microbial contamination rate of cord blood collected for transplantation
Horii et al. Bacillus cereus from blood cultures: virulence genes, antimicrobial susceptibility and risk factors for blood stream infection
Huhulescu et al. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile
Liu et al. Characterization of Salmonella resistome and plasmidome in pork production system in Jiangsu, China
Morio et al. Antimicrobial susceptibilities and clinical sources of Dialister species
Shin et al. Microevolution of Candida albicans strains during catheter-related candidemia
MX2021006136A (es) Ensayo y kit de susceptibilidad antimicrobiana.
Horii et al. Bacillus cereus bloodstream infection in a preterm neonate complicated by late meningitis
Gultekin et al. Distribution of pathogenicity island markers and virulence factors genes of extraintestinal pathogenic Escherichia coli isolates
EP3134538A1 (en) Rapid determination of bacterial susceptibility to an antibiotic at the point of care
Khan et al. Ochrobactrum anthropi sepsis in intensive tertiary care
Zhang et al. Effect of ozonated water on normal vaginal microecology and Lactobacillus
Sacha et al. Expression of Mex AB‐OprM efflux pump system and susceptibility to antibiotics of different P seudomonas aeruginosa clones isolated from patients hospitalized in two intensive care units at University Hospital in Bialystok (northeastern Poland) between January 2002 and December 2009
Guindo et al. Rapid identification of clinically interesting methanogens using an improved MALDI-TOF-MS assay
Rathe et al. Vancomycin‐resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin
Su et al. Bacterial detection in apheresis platelets: blood systems experience with a two‐bottle and one‐bottle culture system
Beauruelle et al. First human case of Fastidiosipila sanguinis infection
Waris et al. Meningitis due to Roseomonas in an immunocompetent adolescent
Yin et al. Characterization of a novel NDM-5-harboring plasmid from a carbapenem-resistant Escherichia coli isolate from China
Coba et al. MP71-03 COMPARISON OF NOVEL DNA-BASED TOOLS FOR BACTERIAL DETECTION IN PATIENTS WITH CHRONIC URINARY TRACT INFECTION (CUTI)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: BAXTER INTERNATIONAL INC (US) , BAXTER HEALTHCARE

Free format text: ENDERECO DO 2O DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110115944/RJ DE 11/11/2011.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2501 DE 11-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.